ENStage 4 breast cancer treatment in Germany centres on drugs acting throughout the body, plus radiotherapy or surgery for specific problems. If you have just learned the disease has spread — to bone, liver, lung or brain — you want a place that will not say «nothing more can be done». Stage 4 means it has spread beyond the breast and nearby lymph nodes, so the aim becomes long-term control rather than one operation, with daily life kept liveable.
Below: re-testing receptors, how a tumour board builds the drug plan, radiotherapy and surgery, supportive care and appointments from abroad. Without metastases, see breast cancer treatment in Germany.
What «stage 4» changes in the plan
Stage 4 means the cancer is treated as a whole-body disease. «Metastatic», the medical term, means cells have travelled through blood or lymph and settled elsewhere, most often in bone, liver and lung, less often the brain. Metastatic breast cancer treatment in Germany starts from this: a liver metastasis is still breast cancer, treated with breast cancer drugs, not liver cancer drugs.
Drug therapy becomes the backbone; local treatment targets problems such as a painful bone lesion, fracture risk or brain metastasis. The honest goal is control of disease and symptoms, and quality of life. Many women live with it for a long time, changing lines of treatment.
Speed is not haste: barring emergencies like a threatened fracture, spinal cord compression or worsening breathlessness, a few days for proper tissue analysis beat starting the wrong drug. See the WHO fact sheet on breast cancer.
The tests that decide the treatment
Three things decide: tissue from the metastasis, imaging and molecular tests. A metastasis can differ from the original tumour, so German centres sample it where possible and re-test ER and PR — whether hormones feed the cancer — and HER2, the growth signal. This can move a woman to another treatment family; even weak HER2 (HER2-low) can later open the way to an antibody-drug conjugate.
Imaging maps the disease: usually CT of chest, abdomen and pelvis plus a bone scan, PET-CT if unclear, brain MRI if symptoms point there. Blood, liver and kidney tests follow, plus a heart check before drugs affecting the heart.
Molecular tests matter where the result changes the drug: inherited changes, above all in BRCA1 and BRCA2; in hormone-sensitive cancer, PIK3CA, AKT1, PTEN and ESR1; in triple-negative cancer, PD-L1. When standard options run low, a molecular tumour board is offered. A clinical trial may be discussed then, but participation is never automatic or guaranteed.
The treatment families and when each is used
The family follows the subtype; each drug is EU-approved for a defined situation. In the commonest form, hormone-receptor-positive and HER2-negative, the usual first step is endocrine therapy plus a CDK4/6 inhibitor, a tablet slowing cell division. Germany’s S3 guideline puts it first because it is gentler than chemotherapy, which comes once hormonal options are exhausted or fail.
In HER2-positive cancer, long-term anti-HER2 treatment is the backbone: first line usually two antibodies with chemotherapy, second line preferably an antibody-drug conjugate. In triple-negative cancer, breast cancer chemotherapy stays central; with PD-L1, immunotherapy joins it first-line; antibody-drug conjugates serve when immunotherapy is unsuitable and later. With an inherited BRCA1/2 mutation and HER2-negative cancer, PARP inhibitor tablets are an option, usually after chemotherapy.
Radiotherapy eases bone pain and protects against fracture; single brain lesions get stereotactic radiotherapy or surgery — see radiotherapy for breast cancer. Bone-strengthening drugs help; surgery treats fractures, threatened fractures and spinal cord compression, while removing liver or lung metastases is considered only in individual cases. Certified centres offer palliative care early, alongside treatment, for pain, nausea, appetite and sleep. The German Cancer Research Center’s information service covers metastatic breast cancer treatment in Germany.
How German breast centres are organised
In stage 4 breast cancer treatment in Germany, a breast centre works as a fixed team. Certified by the German Cancer Society (DKG), it includes breast surgeon, gynaecological and medical oncologists, radiologist, pathologist, radiation oncologist and nuclear medicine physician. Its tumour board meets at least weekly, must discuss metastatic cases and records a written plan; the centre must show a minimum number of new patients yearly. Ask for that written recommendation.
Examples, not a ranking: at the Rotkreuzklinikum in Munich, gynaecology has two chief physicians. Prof. Michael Braun, a DKG-certified senior breast surgeon, heads the interdisciplinary breast centre, covering surgical and drug treatment; Prof. Martin Pölcher leads the gynaecological cancer centre. Prof. Marc Thill, co-author of AGO recommendations on metastatic breast cancer, heads gynaecology and gynaecological oncology at the Agaplesion Frankfurter Diakonie Kliniken. Prof. Jens-Uwe Blohmer heads gynaecology with breast centre at the Charité in Berlin, Prof. Andree Faridi senology at Bonn University Hospital. Compare them: breast cancer hospitals in Germany.
A second opinion can confirm the subtype, correct staging errors or propose another line or a trial, not promise a better outcome. The first line is sometimes agreed from documents before travel; see second opinion from a German doctor.
Frequently asked questions
Can stage 4 breast cancer be cured?
As a rule, no: German guidelines call metastatic breast cancer incurable but treatable. The aim is control and quality of life; in many cases the disease is held back for a long time by changing regimens. How long depends on the subtype, metastasis sites and response.
Is immunotherapy an option?
Only for one subtype: triple-negative tumours that express PD-L1, as first-line treatment with chemotherapy, which is how it is approved in the European Union. It is not standard in hormone-receptor-positive or HER2-positive disease, so PD-L1 is tested on triple-negative tumour tissue before treatment.
Can treatment continue at home?
Part of it can, if the regimen allows: tablets such as CDK4/6 inhibitors with endocrine therapy are taken at home with check-ups. The centre’s discharge letter lists drugs, doses and monitoring, and the oncologist at home needs access to the same medicines.
How AlenMed organises treatment
Your pathology report, imaging and treatment records are translated and sent to breast centres. The reply says whether to re-biopsy, which line is proposed, how long to stay and what can continue at home. For costs, see cost of breast cancer treatment in Germany.
AlenMed works with 86 partner hospitals in 38 cities and 345 doctors; the company office is in Munich. A coordinator handles visa, appointment and interpreter and checks that the discharge letter lists drugs and doses usable by a doctor at home.
For information only, not an offer: the treatment plan is set by the doctor who examines the patient in person.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
